Payment overview · 2025
General Payments
$794.06
25 reported records · 11 companies
Healthcare provider profile · identity verified
Alejandro Paz, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ESCONDIDO, CA · NPI 1760400386
Verified facts
What the public records show
CMS Open Payments records show Alejandro Paz, MD received $794.06 in general payments during 2025 across 25 reported records.
AstraZeneca Pharmaceuticals LP accounted for 36.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $290.13 | 36.5% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $110.98 | 14.0% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $90.41 | 11.4% | 4 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $82.25 | 10.4% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $54.89 | 6.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $47.55 | 6.0% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $38.56 | 4.9% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $32.07 | 4.0% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $18.83 | 2.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.55 | 2.3% | 1 | 2025 |
| BioWound Solutions, Inc. | Unresolved — no canonical attribution shown | $9.84 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $794.06 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $245.14 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $110.98 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $110.98 | 5 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $90.41 | 4 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $54.89 | 1 | 2025 |
Source payment records
|
|||||
| Trodelvy Normalized: trodelvy |
Drug | Gilead Sciences, Inc. | $54.30 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $44.99 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $38.56 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $33.30 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $32.07 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $32.07 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $18.83 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $18.83 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $18.83 | 1 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $18.83 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $18.83 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $18.55 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.09 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $14.25 | 1 | 2025 |
Source payment records
|
|||||
| bio-ConneKt Normalized: bio connekt |
Device | BioWound Solutions, Inc. | $9.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
55 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
52 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
42 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 401 | 114 |
| Lisinopril | Lisinopril | 385 | 111 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 343 | 55 |
| Alprazolam | Alprazolam | 317 | 58 |
| Metformin Hcl | Metformin Hcl | 251 | 82 |
| Amlodipine Besylate | Amlodipine Besylate | 221 | 55 |
| Levothyroxine Sodium | Levothyroxine Sodium | 189 | 48 |
| Gabapentin | Gabapentin | 184 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 177 | 49 |
| Zolpidem Tartrate | Zolpidem Tartrate | 175 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 166 | 50 |
| Oxycodone Hcl | Oxycodone Hcl | 149 | 19 |
| Omeprazole | Omeprazole | 147 | 38 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 129 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 128 | 38 |
| Losartan Potassium | Losartan Potassium | 125 | 42 |
| Metoprolol Tartrate | Metoprolol Tartrate | 123 | 37 |
| Trazodone Hcl | Trazodone Hcl | 114 | 34 |
| Tramadol Hcl | Tramadol Hcl | 99 | 32 |
| Lorazepam | Lorazepam | 96 | 19 |
| Meloxicam | Meloxicam | 96 | 23 |
| Simvastatin | Simvastatin | 95 | 27 |
| Ibuprofen | Ibuprofen | 88 | 25 |
| Doxazosin Mesylate | Doxazosin Mesylate | 82 | 22 |
| Furosemide | Furosemide | 81 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 80 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 79 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 78 | 24 |
| Alendronate Sodium | Alendronate Sodium | 72 | 14 |
| Clonazepam | Clonazepam | 68 | suppressed |
| Finasteride | Finasteride | 68 | 19 |
| Cephalexin | Cephalexin | 60 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 57 | 15 |
| Farxiga | Dapagliflozin Propanediol | 55 | 17 |
| Trulicity | Dulaglutide | 52 | 20 |
| Jardiance | Empagliflozin | 50 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 50 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 47 | 13 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 47 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 45 | 14 |
| Lovastatin | Lovastatin | 44 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 43 | 15 |
| Eliquis | Apixaban | 42 | 11 |
| Baclofen | Baclofen | 41 | suppressed |
| Carvedilol | Carvedilol | 41 | suppressed |
| Mirtazapine | Mirtazapine | 40 | suppressed |
| Temazepam | Temazepam | 39 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 37 | suppressed |
| Diazepam | Diazepam | 36 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 35 | suppressed |
| Potassium Chloride | Potassium Chloride | 35 | 12 |
| Prednisone | Prednisone | 34 | suppressed |
| Levofloxacin | Levofloxacin | 33 | 25 |
| Naproxen | Naproxen | 33 | suppressed |
| Bupropion Xl | Bupropion Hcl | 32 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Amoxicillin | Amoxicillin | 31 | 11 |
| Glipizide | Glipizide | 31 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 30 | suppressed |
| Atenolol | Atenolol | 29 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 12 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 28 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | suppressed |
| Allopurinol | Allopurinol | 26 | suppressed |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 23 |
| Memantine Hcl | Memantine Hcl | 25 | suppressed |
| Rybelsus | Semaglutide | 25 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | 11 |
| Nitroglycerin | Nitroglycerin | 24 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 22 | suppressed |
| Fluconazole | Fluconazole | 22 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Linzess | Linaclotide | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Azithromycin | Azithromycin | 20 | 15 |
| Estradiol | Estradiol | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Ozempic | Semaglutide | 20 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Fentanyl | Fentanyl | 19 | suppressed |
| Methylprednisolone | Methylprednisolone | 19 | 15 |
| Np Thyroid | Thyroid,pork | 19 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 17 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 12 |
| Glimepiride | Glimepiride | 14 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | 11 |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Indomethacin | Indomethacin | 12 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 11 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 11 | suppressed |
| Spravato | Esketamine Hcl | 11 | suppressed |
| Trimethoprim | Trimethoprim | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $794.06 · 25 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPVAXIVE, EVENITY, GARDASIL 9, KISUNLA, M-M-R II, MOUNJARO, NURTEC ODT, Ozempic, PAXLOVID, REXULTI, ROTATEQ, Rybelsus, SHINGRIX, Trodelvy, VAXNEUVANCE, WaveWriter Alpha Prime 16, ZEPBOUND, bio-ConneKt | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error